Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Gilead is a biopharmaceutical company focused on life-threatening infectious diseases, primarily HIV and Hepatitis B. In 2006, the company expanded its portfolio into respiratory and cardiopulmonary diseases through the acquisitions of Corus Pharma, Inc. and Myogen, Inc. Key marketed products include Truvada, Viread, Atripla, Emtriva, Hepsera, and AmBisome.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenues | $3.03 billion | $2.03 billion |
| Product Sales | $2.59 billion | $1.81 billion |
| Royalty Revenue | $416.5 million | $196.9 million |
| Net Income (Loss) | $(1.19 billion) | $813.9 million |
| Operating Cash Flow | $1.22 billion | $705.6 million |
| Cash & Marketable Securities | $1.39 billion | $2.31 billion |
| Convertible Debt Issued | $1.30 billion | None |
| Product Gross Margin | 83% | 86% |
Material Changes vs. Prior Period
- Acquisition-Driven Loss: The company reported a net loss of $1.19 billion in 2006, a reversal from the $813.9 million profit in 2005. This was primarily due to $2.39 billion in non-cash charges for purchased in-process research and development (IPR&D) associated with the acquisitions of Myogen ($2.06 billion) and Corus ($335.6 million).
- Revenue Growth: Total revenues increased 49% year-over-year. Product sales grew 43%, driven by a 110% increase in Truvada sales and the July 2006 launch of Atripla. Royalty revenue more than doubled (112%), largely due to increased Tamiflu royalties from Roche.
- Margin Compression: Product gross margin declined from 86% to 83%. This was attributed to the launch of Atripla (which includes a zero-margin component from partner BMS), inventory write-downs for the Gilead Access Program ($15.8 million), and product mix shifts.
- Accounting Changes: The company adopted SFAS 123R on January 1, 2006, resulting in the expensing of stock-based compensation, which added approximately $133.8 million to operating expenses.
Guidance, Outlook, and Risks
- Regulatory Milestones:
- Ambrisentan (Myogen): FDA granted priority review status with a target decision date of June 2007 for the treatment of pulmonary arterial hypertension (PAH).
- Aztreonam Lysine (Corus): Anticipated filing of a New Drug Application (NDA) for cystic fibrosis in the second half of 2007, pending positive Phase 3 data expected mid-year.
- Tenofovir for Hepatitis B: Anticipated filing for regulatory approval in the U.S. and EU prior to the end of 2007.
- Outlook: Management expects 2007 product sales to continue growing. R&D and SG&A expenses are expected to increase due to internal efforts, the integration of acquired companies, and sales force expansion for the anticipated ambrisentan launch.
- Key Risks:
- Product Concentration: HIV products accounted for approximately 70% of total revenues in 2006. Dependence on Truvada and Viread creates vulnerability to competition and pricing pressures.
- Regulatory & Clinical Risk: Failure to obtain approval for pipeline candidates (ambrisentan, aztreonam) or safety issues with marketed products could materially impact future revenues.
- Generic Competition: Risks include generic entry for Flolan (patent expired) and potential compulsory licensing of Tamiflu or HIV products in developing markets.
- European Credit Risk: Significant accounts receivable balances ($330.5 million) from government-owned customers in Greece, Italy, Portugal, and Spain are subject to payment delays.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of Myogen and Corus operations and the timeline for regulatory approvals of their lead candidates.
- Truvada Growth Sustainability: Assess the durability of Truvada's growth trajectory amidst increasing competition in the HIV NRTI class and potential patient switching to Atripla.
- Tamiflu Royalty Volatility: Monitor Roche's Tamiflu sales volumes, which are subject to seasonal flu severity and pandemic planning stockpiles, as this drives a significant portion of royalty revenue.
- European Receivables: Review the aging of accounts receivable in Southern Europe (Greece, Italy, Portugal, Spain) to assess collection risks and potential bad debt provisions.
- Debt Covenants: Confirm compliance with financial covenants on the $500 million credit facility, noting the recent waiver obtained in January 2007 due to IPR&D charges.